# Adial Pharmaceuticals, Inc.: overview ADIL · Nasdaq · CIK 1513525 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/adil.md) · [Financials](/companies/adil/financials.md) · [Filings](/companies/adil/filings.md) · [Insiders](/companies/adil/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.38)](/filings/0001213900-25-109979.md) | not reported | [(8.52)](/filings/0001213900-26-053907.md) | [(4.61)](/filings/0001213900-26-111121.md) | [(0.08)](/filings/0001213900-25-109979.md) | not reported | [(1.48)](/filings/0001213900-26-053907.md) | [(11.25)](/filings/0001213900-26-111121.md) | | Free cash flow | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(1.04)](/filings/0001213900-23-024719.md) | [(12.71)](/filings/0001213900-24-028701.md) | [(3.60)](/filings/0001213900-25-019771.md) | [(68.01)](/filings/0001213900-26-024175.md) | [(11.93)](/filings/0001213900-26-024175.md) | | Free cash flow | $m | [(12.0)](/filings/0001213900-23-024719.md) | not reported | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/adil/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [JANE STREET GROUP, LLC](/funds/1595888.md) | 2026-06-30 | $82.2k | 32,119 | | New +32,119 | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $75.6k | 29,547 | | New +29,547 | | [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $49.0k | 19,147 | | Added +18,605 | | [StoneX Group Inc.](/funds/913760.md) | 2026-06-30 | $35.7k | 19,699 | | New +19,699 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $31.7k | 12,393 | | Reduced −11,856 | | [China Universal Asset Management Co., Ltd.](/funds/1906594.md) | 2026-06-30 | $20.5k | 8,000 | | New +8,000 | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $15.1k | 5,879 | | Unchanged | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $14.9k | 5,831 | | Added +5,470 | | [Manchester Capital Management LLC](/funds/1393389.md) | 2026-06-30 | $4.9k | 1,923 | | Unchanged | | [Tower Research Capital LLC (TRC)](/funds/1533421.md) | 2026-06-30 | $3.6k | 1,419 | | Added +63 | ## Recent filings [All 570 filings](/companies/adil/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-28 | 16:30 ET | [8-K](/filings/0001213900-26-113337.md) | 5.02 Departure or appointment of officers or directors; 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-26-113337 | | 2026-10-21 | 20:25 ET | [10-Q/A](/filings/0001213900-26-111121.md) | Quarterly report, amended, period 2026-06-30 | 0001213900-26-111121 | | 2026-10-16 | 17:15 ET | [8-K](/filings/0001213900-26-110349.md) | 8.01 Other events | 0001213900-26-110349 | | 2026-10-02 | 16:16 ET | [8-K](/filings/0001213900-26-106395.md) | 8.01 Other events | 0001213900-26-106395 | | 2026-09-18 | 16:27 ET | [8-K](/filings/0001213900-26-101434.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001213900-26-101434 | | 2026-09-16 | 17:08 ET | [8-K](/filings/0001213900-26-100574.md) | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-26-100574 | | 2026-08-25 | 16:33 ET | [8-K](/filings/0001213900-26-093544.md) | 3.02 Unregistered sale of equity | 0001213900-26-093544 | | 2026-08-24 | 16:05 ET | [DEF 14A](/filings/0001213900-26-093019.md) | Proxy statement, period 2026-09-17 | 0001213900-26-093019 | | 2026-08-21 | 17:17 ET | [8-K](/filings/0001213900-26-092690.md) | 3.01 Delisting notice | 0001213900-26-092690 | | 2026-08-17 | 07:17 ET | [8-K](/filings/0001213900-26-090482.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001213900-26-090482 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001213900-26-024175.md), filed Mar 5, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1513525 - Tickers: ADIL - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 30, 2026, 20:45 ET. No prices; not investment advice.